Onconetix, Inc.
Get $10 bonus on your first $100 deposit for ONCO
Get $10 bonus on your first $100 deposit for ONCO
Onconetix, Inc. (ONCO) Stock Competitors & Peer Comparison
See (ONCO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ONCO | $0.73 | +7.52% | 2.5M | -0.01 | -$82.80 | N/A |
| VRTX | $437.67 | +0.25% | 111.3B | 28.56 | $15.32 | N/A |
| REGN | $746.58 | -0.10% | 77.6B | 17.89 | $41.73 | +0.24% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $793.22 | -1.51% | 49.1B | 40.45 | $19.61 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $310.58 | +0.70% | 41.4B | 132.73 | $2.34 | N/A |
| INSM | $144.48 | +2.48% | 31.2B | -22.47 | -$6.43 | N/A |
| RVMD | $141.50 | -4.97% | 28B | -23.74 | -$5.96 | N/A |
| BNTX | $108.60 | -2.69% | 27.3B | -19.57 | -$5.55 | N/A |
Stock Comparison
ONCO vs VRTX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, VRTX has a market cap of 111.3B. Regarding current trading prices, ONCO is priced at $0.73, while VRTX trades at $437.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas VRTX's P/E ratio is 28.56. In terms of profitability, ONCO's ROE is -1.90%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ONCO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check VRTX's competition here
ONCO vs REGN Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, REGN has a market cap of 77.6B. Regarding current trading prices, ONCO is priced at $0.73, while REGN trades at $746.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas REGN's P/E ratio is 17.89. In terms of profitability, ONCO's ROE is -1.90%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ONCO is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check REGN's competition here
ONCO vs VRNA Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ONCO is priced at $0.73, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ONCO's ROE is -1.90%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ONCO is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check VRNA's competition here
ONCO vs ARGX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ARGX has a market cap of 49.1B. Regarding current trading prices, ONCO is priced at $0.73, while ARGX trades at $793.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ARGX's P/E ratio is 40.45. In terms of profitability, ONCO's ROE is -1.90%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, ONCO is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ARGX's competition here
ONCO vs SGEN Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ONCO is priced at $0.73, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ONCO's ROE is -1.90%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ONCO is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check SGEN's competition here
ONCO vs ALNY Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ALNY has a market cap of 41.4B. Regarding current trading prices, ONCO is priced at $0.73, while ALNY trades at $310.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ALNY's P/E ratio is 132.73. In terms of profitability, ONCO's ROE is -1.90%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, ONCO is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ALNY's competition here
ONCO vs INSM Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, INSM has a market cap of 31.2B. Regarding current trading prices, ONCO is priced at $0.73, while INSM trades at $144.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas INSM's P/E ratio is -22.47. In terms of profitability, ONCO's ROE is -1.90%, compared to INSM's ROE of -1.68%. Regarding short-term risk, ONCO is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check INSM's competition here
ONCO vs RVMD Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, RVMD has a market cap of 28B. Regarding current trading prices, ONCO is priced at $0.73, while RVMD trades at $141.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas RVMD's P/E ratio is -23.74. In terms of profitability, ONCO's ROE is -1.90%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, ONCO is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RVMD's competition here
ONCO vs BNTX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, BNTX has a market cap of 27.3B. Regarding current trading prices, ONCO is priced at $0.73, while BNTX trades at $108.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas BNTX's P/E ratio is -19.57. In terms of profitability, ONCO's ROE is -1.90%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, ONCO is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BNTX's competition here
ONCO vs UTHR Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, UTHR has a market cap of 25.2B. Regarding current trading prices, ONCO is priced at $0.73, while UTHR trades at $574.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas UTHR's P/E ratio is 20.59. In terms of profitability, ONCO's ROE is -1.90%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ONCO is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check UTHR's competition here
ONCO vs MRNA Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, MRNA has a market cap of 22B. Regarding current trading prices, ONCO is priced at $0.73, while MRNA trades at $55.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas MRNA's P/E ratio is -7.66. In terms of profitability, ONCO's ROE is -1.90%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, ONCO is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MRNA's competition here
ONCO vs RPRX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, RPRX has a market cap of 21.3B. Regarding current trading prices, ONCO is priced at $0.73, while RPRX trades at $49.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas RPRX's P/E ratio is 27.93. In terms of profitability, ONCO's ROE is -1.90%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, ONCO is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RPRX's competition here
ONCO vs ROIV Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ROIV has a market cap of 20.9B. Regarding current trading prices, ONCO is priced at $0.73, while ROIV trades at $29.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ROIV's P/E ratio is -24.91. In terms of profitability, ONCO's ROE is -1.90%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, ONCO is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ROIV's competition here
ONCO vs BGNE Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ONCO is priced at $0.73, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ONCO's ROE is -1.90%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, ONCO is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BGNE's competition here
ONCO vs INCY Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, INCY has a market cap of 19.3B. Regarding current trading prices, ONCO is priced at $0.73, while INCY trades at $96.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas INCY's P/E ratio is 15.09. In terms of profitability, ONCO's ROE is -1.90%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ONCO is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check INCY's competition here
ONCO vs SMMT Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, SMMT has a market cap of 19B. Regarding current trading prices, ONCO is priced at $0.73, while SMMT trades at $24.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas SMMT's P/E ratio is -17.05. In terms of profitability, ONCO's ROE is -1.90%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, ONCO is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ONCO.Check SMMT's competition here
ONCO vs DNA-WT Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ONCO is priced at $0.73, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ONCO's ROE is -1.90%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, ONCO is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check DNA-WT's competition here
ONCO vs GMAB Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, GMAB has a market cap of 17.1B. Regarding current trading prices, ONCO is priced at $0.73, while GMAB trades at $27.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas GMAB's P/E ratio is 17.98. In terms of profitability, ONCO's ROE is -1.90%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ONCO is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check GMAB's competition here
ONCO vs BBIO Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, BBIO has a market cap of 14.4B. Regarding current trading prices, ONCO is priced at $0.73, while BBIO trades at $74.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas BBIO's P/E ratio is -19.69. In terms of profitability, ONCO's ROE is -1.90%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, ONCO is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BBIO's competition here
ONCO vs ASND Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, ONCO is priced at $0.73, while ASND trades at $231.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ASND's P/E ratio is -51.92. In terms of profitability, ONCO's ROE is -1.90%, compared to ASND's ROE of +1.28%. Regarding short-term risk, ONCO is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ASND's competition here
ONCO vs KRTX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ONCO is priced at $0.73, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ONCO's ROE is -1.90%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ONCO is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check KRTX's competition here
ONCO vs JAZZ Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, JAZZ has a market cap of 12.5B. Regarding current trading prices, ONCO is priced at $0.73, while JAZZ trades at $202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas JAZZ's P/E ratio is -34.66. In terms of profitability, ONCO's ROE is -1.90%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, ONCO is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check JAZZ's competition here
ONCO vs IONS Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, ONCO is priced at $0.73, while IONS trades at $74.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas IONS's P/E ratio is -31.44. In terms of profitability, ONCO's ROE is -1.90%, compared to IONS's ROE of -0.69%. Regarding short-term risk, ONCO is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check IONS's competition here
ONCO vs EXEL Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, EXEL has a market cap of 12.2B. Regarding current trading prices, ONCO is priced at $0.73, while EXEL trades at $46.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas EXEL's P/E ratio is 16.85. In terms of profitability, ONCO's ROE is -1.90%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, ONCO is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check EXEL's competition here
ONCO vs MDGL Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, ONCO is priced at $0.73, while MDGL trades at $529.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas MDGL's P/E ratio is -41.15. In terms of profitability, ONCO's ROE is -1.90%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, ONCO is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MDGL's competition here
ONCO vs RNAM Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ONCO is priced at $0.73, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ONCO's ROE is -1.90%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ONCO is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RNAM's competition here
ONCO vs BMRN Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, ONCO is priced at $0.73, while BMRN trades at $54.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas BMRN's P/E ratio is 30.08. In terms of profitability, ONCO's ROE is -1.90%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, ONCO is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BMRN's competition here
ONCO vs ARWR Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ARWR has a market cap of 10.4B. Regarding current trading prices, ONCO is priced at $0.73, while ARWR trades at $73.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ARWR's P/E ratio is 46.20. In terms of profitability, ONCO's ROE is -1.90%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, ONCO is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ARWR's competition here
ONCO vs RXDX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ONCO is priced at $0.73, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ONCO's ROE is -1.90%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ONCO is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RXDX's competition here
ONCO vs AXSM Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, AXSM has a market cap of 9.5B. Regarding current trading prices, ONCO is priced at $0.73, while AXSM trades at $186.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas AXSM's P/E ratio is -50.52. In terms of profitability, ONCO's ROE is -1.90%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, ONCO is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check AXSM's competition here
ONCO vs TECH Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, ONCO is priced at $0.73, while TECH trades at $58.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas TECH's P/E ratio is 108.48. In terms of profitability, ONCO's ROE is -1.90%, compared to TECH's ROE of +0.04%. Regarding short-term risk, ONCO is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check TECH's competition here
ONCO vs PCVX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, ONCO is priced at $0.73, while PCVX trades at $60.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas PCVX's P/E ratio is -10.80. In terms of profitability, ONCO's ROE is -1.90%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, ONCO is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check PCVX's competition here
ONCO vs IMGN Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ONCO is priced at $0.73, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ONCO's ROE is -1.90%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ONCO is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check IMGN's competition here
ONCO vs BPMC Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ONCO is priced at $0.73, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ONCO's ROE is -1.90%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ONCO is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BPMC's competition here
ONCO vs IBRX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, ONCO is priced at $0.73, while IBRX trades at $8.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas IBRX's P/E ratio is -21.24. In terms of profitability, ONCO's ROE is -1.90%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, ONCO is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check IBRX's competition here
ONCO vs CERE Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ONCO is priced at $0.73, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CERE's P/E ratio is -16.47. In terms of profitability, ONCO's ROE is -1.90%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ONCO is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CERE's competition here
ONCO vs CYTK Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, ONCO is priced at $0.73, while CYTK trades at $66.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CYTK's P/E ratio is -10.13. In terms of profitability, ONCO's ROE is -1.90%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, ONCO is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CYTK's competition here
ONCO vs HALO Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, ONCO is priced at $0.73, while HALO trades at $68.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas HALO's P/E ratio is 26.72. In terms of profitability, ONCO's ROE is -1.90%, compared to HALO's ROE of +0.93%. Regarding short-term risk, ONCO is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check HALO's competition here
ONCO vs KRYS Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, KRYS has a market cap of 8.1B. Regarding current trading prices, ONCO is priced at $0.73, while KRYS trades at $275.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas KRYS's P/E ratio is 40.40. In terms of profitability, ONCO's ROE is -1.90%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ONCO is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check KRYS's competition here
ONCO vs NUVL Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, NUVL has a market cap of 8B. Regarding current trading prices, ONCO is priced at $0.73, while NUVL trades at $108.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas NUVL's P/E ratio is -18.61. In terms of profitability, ONCO's ROE is -1.90%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, ONCO is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check NUVL's competition here
ONCO vs ABVX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ABVX has a market cap of 7.6B. Regarding current trading prices, ONCO is priced at $0.73, while ABVX trades at $115.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ABVX's P/E ratio is -20.31. In terms of profitability, ONCO's ROE is -1.90%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, ONCO is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ABVX's competition here
ONCO vs MTSR Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ONCO is priced at $0.73, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ONCO's ROE is -1.90%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ONCO is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MTSR's competition here
ONCO vs KYMR Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, KYMR has a market cap of 7.2B. Regarding current trading prices, ONCO is priced at $0.73, while KYMR trades at $88.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas KYMR's P/E ratio is -24.06. In terms of profitability, ONCO's ROE is -1.90%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, ONCO is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check KYMR's competition here
ONCO vs PRAX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, ONCO is priced at $0.73, while PRAX trades at $337.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas PRAX's P/E ratio is -25.02. In terms of profitability, ONCO's ROE is -1.90%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, ONCO is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check PRAX's competition here
ONCO vs MRUS Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ONCO is priced at $0.73, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ONCO's ROE is -1.90%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ONCO is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MRUS's competition here
ONCO vs PTGX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, ONCO is priced at $0.73, while PTGX trades at $105.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas PTGX's P/E ratio is -51.49. In terms of profitability, ONCO's ROE is -1.90%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, ONCO is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check PTGX's competition here
ONCO vs ERAS Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ERAS has a market cap of 6.7B. Regarding current trading prices, ONCO is priced at $0.73, while ERAS trades at $21.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ERAS's P/E ratio is -49.20. In terms of profitability, ONCO's ROE is -1.90%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, ONCO is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ONCO.Check ERAS's competition here
ONCO vs ACLX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ONCO is priced at $0.73, while ACLX trades at $115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ACLX's P/E ratio is -28.26. In terms of profitability, ONCO's ROE is -1.90%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ONCO is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ACLX's competition here
ONCO vs BLTE Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, ONCO is priced at $0.73, while BLTE trades at $167.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas BLTE's P/E ratio is -72.16. In terms of profitability, ONCO's ROE is -1.90%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, ONCO is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BLTE's competition here
ONCO vs RETA Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ONCO is priced at $0.73, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas RETA's P/E ratio is -66.29. In terms of profitability, ONCO's ROE is -1.90%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ONCO is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RETA's competition here
ONCO vs TGTX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, TGTX has a market cap of 6.1B. Regarding current trading prices, ONCO is priced at $0.73, while TGTX trades at $38.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas TGTX's P/E ratio is 13.83. In terms of profitability, ONCO's ROE is -1.90%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, ONCO is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check TGTX's competition here
ONCO vs IMVT Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, IMVT has a market cap of 6B. Regarding current trading prices, ONCO is priced at $0.73, while IMVT trades at $29.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas IMVT's P/E ratio is -11.04. In terms of profitability, ONCO's ROE is -1.90%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, ONCO is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check IMVT's competition here
ONCO vs CELC Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CELC has a market cap of 5.9B. Regarding current trading prices, ONCO is priced at $0.73, while CELC trades at $122.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CELC's P/E ratio is -32.22. In terms of profitability, ONCO's ROE is -1.90%, compared to CELC's ROE of -2.03%. Regarding short-term risk, ONCO is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CELC's competition here
ONCO vs COGT Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, ONCO is priced at $0.73, while COGT trades at $36.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas COGT's P/E ratio is -16.85. In terms of profitability, ONCO's ROE is -1.90%, compared to COGT's ROE of -1.00%. Regarding short-term risk, ONCO is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check COGT's competition here
ONCO vs CGON Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, ONCO is priced at $0.73, while CGON trades at $69.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CGON's P/E ratio is -33.60. In terms of profitability, ONCO's ROE is -1.90%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ONCO is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CGON's competition here
ONCO vs CNTA Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, ONCO is priced at $0.73, while CNTA trades at $39.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CNTA's P/E ratio is -27.03. In terms of profitability, ONCO's ROE is -1.90%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, ONCO is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CNTA's competition here
ONCO vs PTCT Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, ONCO is priced at $0.73, while PTCT trades at $70.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas PTCT's P/E ratio is 8.26. In terms of profitability, ONCO's ROE is -1.90%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, ONCO is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check PTCT's competition here
ONCO vs RYTM Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, RYTM has a market cap of 5.8B. Regarding current trading prices, ONCO is priced at $0.73, while RYTM trades at $85.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas RYTM's P/E ratio is -27.39. In terms of profitability, ONCO's ROE is -1.90%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, ONCO is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RYTM's competition here
ONCO vs CAI Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CAI has a market cap of 5.8B. Regarding current trading prices, ONCO is priced at $0.73, while CAI trades at $20.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CAI's P/E ratio is -6.37. In terms of profitability, ONCO's ROE is -1.90%, compared to CAI's ROE of +0.25%. Regarding short-term risk, ONCO is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CAI's competition here
ONCO vs ALKS Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ALKS has a market cap of 5.6B. Regarding current trading prices, ONCO is priced at $0.73, while ALKS trades at $33.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ALKS's P/E ratio is 23.59. In terms of profitability, ONCO's ROE is -1.90%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, ONCO is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ALKS's competition here
ONCO vs CDTX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ONCO is priced at $0.73, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ONCO's ROE is -1.90%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ONCO is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CDTX's competition here
ONCO vs ABCM Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ONCO is priced at $0.73, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ONCO's ROE is -1.90%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ONCO is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ABCM's competition here
ONCO vs ISEE Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ONCO is priced at $0.73, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ONCO's ROE is -1.90%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ONCO is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ISEE's competition here
ONCO vs SRRK Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, SRRK has a market cap of 5.4B. Regarding current trading prices, ONCO is priced at $0.73, while SRRK trades at $47.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas SRRK's P/E ratio is -14.39. In terms of profitability, ONCO's ROE is -1.90%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, ONCO is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check SRRK's competition here
ONCO vs CRSP Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, ONCO is priced at $0.73, while CRSP trades at $56.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CRSP's P/E ratio is -8.72. In terms of profitability, ONCO's ROE is -1.90%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, ONCO is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CRSP's competition here
ONCO vs APLS Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, ONCO is priced at $0.73, while APLS trades at $40.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas APLS's P/E ratio is 227.17. In terms of profitability, ONCO's ROE is -1.90%, compared to APLS's ROE of +0.08%. Regarding short-term risk, ONCO is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check APLS's competition here
ONCO vs FBIOX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, ONCO is priced at $0.73, while FBIOX trades at $25.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ONCO's ROE is -1.90%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ONCO is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check FBIOX's competition here
ONCO vs APGE Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, ONCO is priced at $0.73, while APGE trades at $90.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas APGE's P/E ratio is -21.49. In terms of profitability, ONCO's ROE is -1.90%, compared to APGE's ROE of -0.37%. Regarding short-term risk, ONCO is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check APGE's competition here
ONCO vs CORT Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CORT has a market cap of 5B. Regarding current trading prices, ONCO is priced at $0.73, while CORT trades at $46.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CORT's P/E ratio is 56.79. In terms of profitability, ONCO's ROE is -1.90%, compared to CORT's ROE of +0.15%. Regarding short-term risk, ONCO is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CORT's competition here
ONCO vs LEGN Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, LEGN has a market cap of 4.8B. Regarding current trading prices, ONCO is priced at $0.73, while LEGN trades at $25.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas LEGN's P/E ratio is -16.01. In terms of profitability, ONCO's ROE is -1.90%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, ONCO is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check LEGN's competition here
ONCO vs TERN Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ONCO is priced at $0.73, while TERN trades at $52.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas TERN's P/E ratio is -51.30. In terms of profitability, ONCO's ROE is -1.90%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ONCO is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check TERN's competition here
ONCO vs MIRM Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, ONCO is priced at $0.73, while MIRM trades at $94.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas MIRM's P/E ratio is -200.66. In terms of profitability, ONCO's ROE is -1.90%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, ONCO is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MIRM's competition here
ONCO vs FOLD Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ONCO is priced at $0.73, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas FOLD's P/E ratio is -160.67. In terms of profitability, ONCO's ROE is -1.90%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ONCO is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check FOLD's competition here
ONCO vs LGND Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, LGND has a market cap of 4.5B. Regarding current trading prices, ONCO is priced at $0.73, while LGND trades at $226.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas LGND's P/E ratio is 37.01. In terms of profitability, ONCO's ROE is -1.90%, compared to LGND's ROE of +0.14%. Regarding short-term risk, ONCO is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check LGND's competition here
ONCO vs AKRO Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ONCO is priced at $0.73, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ONCO's ROE is -1.90%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ONCO is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check AKRO's competition here
ONCO vs XENE Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, ONCO is priced at $0.73, while XENE trades at $56.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas XENE's P/E ratio is -12.99. In terms of profitability, ONCO's ROE is -1.90%, compared to XENE's ROE of -0.56%. Regarding short-term risk, ONCO is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check XENE's competition here
ONCO vs ALPN Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ONCO is priced at $0.73, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ONCO's ROE is -1.90%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ONCO is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ALPN's competition here
ONCO vs SYRE Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, ONCO is priced at $0.73, while SYRE trades at $73.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas SYRE's P/E ratio is -36.87. In terms of profitability, ONCO's ROE is -1.90%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, ONCO is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check SYRE's competition here
ONCO vs OPT Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ONCO is priced at $0.73, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas OPT's P/E ratio is -1.52. In terms of profitability, ONCO's ROE is -1.90%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ONCO is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check OPT's competition here
ONCO vs MRTX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ONCO is priced at $0.73, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ONCO's ROE is -1.90%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ONCO is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check MRTX's competition here
ONCO vs CRNX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CRNX has a market cap of 4.1B. Regarding current trading prices, ONCO is priced at $0.73, while CRNX trades at $39.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CRNX's P/E ratio is -7.90. In terms of profitability, ONCO's ROE is -1.90%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, ONCO is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CRNX's competition here
ONCO vs VKTX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, ONCO is priced at $0.73, while VKTX trades at $34.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas VKTX's P/E ratio is -10.74. In terms of profitability, ONCO's ROE is -1.90%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, ONCO is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check VKTX's competition here
ONCO vs ACAD Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, ONCO is priced at $0.73, while ACAD trades at $22.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ACAD's P/E ratio is 9.67. In terms of profitability, ONCO's ROE is -1.90%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, ONCO is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ACAD's competition here
ONCO vs RYZB Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ONCO is priced at $0.73, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ONCO's ROE is -1.90%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ONCO is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check RYZB's competition here
ONCO vs CBAY Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ONCO is priced at $0.73, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ONCO's ROE is -1.90%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ONCO is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CBAY's competition here
ONCO vs TVTX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, TVTX has a market cap of 3.7B. Regarding current trading prices, ONCO is priced at $0.73, while TVTX trades at $40.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas TVTX's P/E ratio is -70.33. In terms of profitability, ONCO's ROE is -1.90%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, ONCO is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check TVTX's competition here
ONCO vs NAMS Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, ONCO is priced at $0.73, while NAMS trades at $31.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas NAMS's P/E ratio is -18.57. In terms of profitability, ONCO's ROE is -1.90%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, ONCO is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check NAMS's competition here
ONCO vs SWTX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ONCO is priced at $0.73, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ONCO's ROE is -1.90%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ONCO is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check SWTX's competition here
ONCO vs DNTH Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, DNTH has a market cap of 3.5B. Regarding current trading prices, ONCO is priced at $0.73, while DNTH trades at $91.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas DNTH's P/E ratio is -21.74. In terms of profitability, ONCO's ROE is -1.90%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, ONCO is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check DNTH's competition here
ONCO vs TLX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, ONCO is priced at $0.73, while TLX trades at $10.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas TLX's P/E ratio is -516.50. In terms of profitability, ONCO's ROE is -1.90%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ONCO is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check TLX's competition here
ONCO vs EWTX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, EWTX has a market cap of 3.5B. Regarding current trading prices, ONCO is priced at $0.73, while EWTX trades at $32.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas EWTX's P/E ratio is -19.74. In terms of profitability, ONCO's ROE is -1.90%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, ONCO is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check EWTX's competition here
ONCO vs LQDA Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, ONCO is priced at $0.73, while LQDA trades at $37.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas LQDA's P/E ratio is -46.32. In terms of profitability, ONCO's ROE is -1.90%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, ONCO is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check LQDA's competition here
ONCO vs DYN Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, DYN has a market cap of 3.2B. Regarding current trading prices, ONCO is priced at $0.73, while DYN trades at $19.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas DYN's P/E ratio is -5.67. In terms of profitability, ONCO's ROE is -1.90%, compared to DYN's ROE of -0.61%. Regarding short-term risk, ONCO is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check DYN's competition here
ONCO vs BEAM Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, BEAM has a market cap of 3.2B. Regarding current trading prices, ONCO is priced at $0.73, while BEAM trades at $31.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas BEAM's P/E ratio is -39.12. In terms of profitability, ONCO's ROE is -1.90%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, ONCO is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check BEAM's competition here
ONCO vs DNLI Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, ONCO is priced at $0.73, while DNLI trades at $20.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas DNLI's P/E ratio is -6.82. In terms of profitability, ONCO's ROE is -1.90%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, ONCO is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check DNLI's competition here
ONCO vs KNSA Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, KNSA has a market cap of 3.2B. Regarding current trading prices, ONCO is priced at $0.73, while KNSA trades at $43.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas KNSA's P/E ratio is 57.39. In terms of profitability, ONCO's ROE is -1.90%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, ONCO is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check KNSA's competition here
ONCO vs CPRX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, CPRX has a market cap of 3.2B. Regarding current trading prices, ONCO is priced at $0.73, while CPRX trades at $25.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas CPRX's P/E ratio is 15.26. In terms of profitability, ONCO's ROE is -1.90%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ONCO is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check CPRX's competition here
ONCO vs ALMS Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, ALMS has a market cap of 3.2B. Regarding current trading prices, ONCO is priced at $0.73, while ALMS trades at $25.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas ALMS's P/E ratio is -9.05. In terms of profitability, ONCO's ROE is -1.90%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, ONCO is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check ALMS's competition here
ONCO vs TNGX Comparison April 2026
ONCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ONCO stands at 2.5M. In comparison, TNGX has a market cap of 3.1B. Regarding current trading prices, ONCO is priced at $0.73, while TNGX trades at $26.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ONCO currently has a P/E ratio of -0.01, whereas TNGX's P/E ratio is -30.97. In terms of profitability, ONCO's ROE is -1.90%, compared to TNGX's ROE of -0.50%. Regarding short-term risk, ONCO is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for ONCO.Check TNGX's competition here